Clinical Trials Logo

BRAF V600E clinical trials

View clinical trials related to BRAF V600E.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT04534283 Terminated - Cancer Clinical Trials

A Basket Trial of an ERK1/2 Inhibitor (LY3214996) in Combination With Abemaciclib.

Start date: October 5, 2020
Phase: Phase 2
Study type: Interventional

The purpose of CTO-IUSCC-0730 study is to assess the clinical efficacy of LY3214996 in combination with abemaciclib at the recommended phase 2 dose of LY3214996 200 mg orally daily and abemaciclib 150 mg orally twice daily. Patients will be treated until evidence of disease progression, non-compliance with study protocol, unacceptable major toxicity, at subject's own request for withdrawal, or if the study closes for any reason.

NCT ID: NCT03973918 Terminated - Glioblastoma Clinical Trials

Study of Binimetinib With Encorafenib in Adults With Recurrent BRAF V600-Mutated HGG

BRAF
Start date: July 29, 2019
Phase: Phase 2
Study type: Interventional

The goal of this study is to estimate the efficacy of encorafenib and binimetinib as measured by radiographic response in recurrent high-grade primary brain tumors.

NCT ID: NCT03593993 Terminated - Glioblastoma Clinical Trials

A Biospecimen Collection Study in BRAF-V600E Mutated Recurrent Gliomas

Start date: May 19, 2018
Phase:
Study type: Observational

This is a surgical biospecimen collection study. The purpose of this study is to understand how much of two drugs (dabrafenib and trametinib) are able to penetrate brain tumors and turn off the RAF signaling pathway. This is important because these drugs are currently FDA approved for other tumors and may have efficacy in brain tumors with the BRAF V600E mutation.